326 related articles for article (PubMed ID: 33692613)
21. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
[TBL] [Abstract][Full Text] [Related]
22. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.
Jeffres MN; Isakow W; Doherty JA; McKinnon PS; Ritchie DJ; Micek ST; Kollef MH
Chest; 2006 Oct; 130(4):947-55. PubMed ID: 17035423
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
25. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
26. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
27. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
[TBL] [Abstract][Full Text] [Related]
28. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
29. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
30. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
[TBL] [Abstract][Full Text] [Related]
32. A Retrospective Review of the Efficiency of First-Dose Therapeutic Drug Monitoring of Gentamicin, Amikacin, and Vancomycin in the Pediatric Population.
Lim WXS; Chua WBB; Chua JM; Lee Q; Chan JW; Sultana R; Poh BH
J Clin Pharmacol; 2020 Jan; 60(1):7-15. PubMed ID: 31448430
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
Al-Sulaiti FK; Nader AM; Saad MO; Shaukat A; Parakadavathu R; Elzubair A; Al-Badriyeh D; Elewa H; Awaisu A
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):639-652. PubMed ID: 30919233
[TBL] [Abstract][Full Text] [Related]
34. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations.
Brown ML; Hutchison AM; McAtee AM; Gaillard PR; Childress DT
Am J Health Syst Pharm; 2017 Jul; 74(14):1067-1075. PubMed ID: 28522643
[TBL] [Abstract][Full Text] [Related]
35. Individualized dosing of vancomycin in geriatric patients.
Suchánková H; Lečbychová K; Strojil J; Fürst T
Epidemiol Mikrobiol Imunol; 2020; 69(4):172-180. PubMed ID: 33445941
[TBL] [Abstract][Full Text] [Related]
36. Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients.
Wong S; Selby PR; Reuter SE
Pharmacol Res Perspect; 2024 Aug; 12(4):e1231. PubMed ID: 38940223
[TBL] [Abstract][Full Text] [Related]
37. Switching From Intermittent to Continuous Infusion of Vancomycin in Critically Ill Patients: Toward a More Robust Exposure.
van Maarseveen EM; Gipmans S; Vasbinder E; Petjak M; van Zanten AR
Ther Drug Monit; 2016 Jun; 38(3):398-401. PubMed ID: 26926670
[TBL] [Abstract][Full Text] [Related]
38. A Brief Review of Pharmacokinetic Assessments of Vancomycin in Special Groups of Patients with Altered Pharmacokinetic Parameters.
Ghasemiyeh P; Vazin A; Mohammadi-Samani S
Curr Drug Saf; 2023; 18(4):425-439. PubMed ID: 35927907
[TBL] [Abstract][Full Text] [Related]
39. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.
Darko W; Medicis JJ; Smith A; Guharoy R; Lehmann DE
Pharmacotherapy; 2003 May; 23(5):643-50. PubMed ID: 12741439
[TBL] [Abstract][Full Text] [Related]
40. Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.
Kim J; Walker SA; Iaboni DC; Walker SE; Elligsen M; Dunn MS; Allen VG; Simor A
Antimicrob Agents Chemother; 2014 May; 58(5):2830-40. PubMed ID: 24614381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
